SFEMG improvement with remission in the cancer-associated Lambert-Eaton myasthenic syndrome.
In two patients with the Lambert-Eaton myasthenic syndrome (LEMS) and small-cell lung carcinoma (SLLC), therapy for LEMS was effective when combined with cancer therapy. The serial SFEMG tests showed a corresponding improvement with remission of the LEMS and proved to be a better and earlier indicator of the changing clinical status than the repetitive nerve stimulation test. Thus, we conclude that the SFEMG is useful in the follow-up evaluation of patients with this condition.
Oh
S J
SJ
Department of Neurology, University of Alabama, Birmingham 35294.
D018288:Carcinoma, Small Cell / Q000503:physiopathology*; D004576:Electromyography; D005260:Female; D006801:Humans; D015624:Lambert-Eaton Myasthenic Syndrome / Q000503:physiopathology*; D008175:Lung Neoplasms / Q000503:physiopathology*; D008875:Middle Aged; D009132:Muscles / Q000503:physiopathology; D012074:Remission Induction